News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Newron Pharmaceuticals Starts Preclinicals on Compound with Psychiatric Treatment Potential
December 3, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH (Thomson Financial) - Newron Pharmaceuticals Spa said it has started preclinical development of a compound called NW-3509, which could potentially be used to treat psychiatric and neurological diseases, such as acute mania.
Twitter
LinkedIn
Facebook
Email
Print
Preclinical
Europe
MORE ON THIS TOPIC
Huntington’s disease
UniQure files for FDA, UK approval of first gene therapy for Huntington’s disease
September 2, 2026
·
3 min read
·
Heather McKenzie
IN PARTNERSHIP WITH GEMPHARMATECH
Beyond GLP‑1s: The race for next‑gen obesity drugs starts in the preclinical models
September 2, 2026
·
5 min read
·
Jennifer C. Smith-Parker
Regulatory
Tavneos no longer available for new patients in UK as Amgen awaits FDA hearing
September 2, 2026
·
2 min read
·
Tristan Manalac
Multiple sclerosis
Novartis’ Rhapsido cuts MS progression in Phase 3 trial, teeing up Roche battle
September 2, 2026
·
2 min read
·
Tristan Manalac
